Ask AI

HOPA 2026

 
Virtual Simulcast
 
In-Person
 
Free CME/CE Credits

New Orleans Annual Hematology/Oncology Pharmacy Events 2026

Join us live or virtually during HOPA 2026 for 1 of 6 dynamic, pharmacy‑focused educational sessions designed to keep you at the forefront of oncology practice. Whether you’re interested in subcutaneous multitumor IO, NDMM, HR-positive/HER2‑negative AE management, myeloma therapeutics, HR-positive/HER2‑negative EBC, or bispecific antibodies in myeloma, these expert‑led programs offer timely insights you can put into practice right away. Every session is free, accredited, and tailored to support the evolving needs of oncology pharmacists—so pick the topics that matter most to you and elevate your expertise.

 

Dates Friday, March 27, 2026
Thursday, April 30, 2026
Wednesday, May 27, 2026

 

Time Varies per Event
Timezone Converter ›

 

Location Ernest N. Morial Convention Center
900 Convention Center Blvd.
New Orleans, Louisiana 70130
388-390, third floor above Hall J

Event Schedule

Attend in-person or via virtual simulcast.

Featured Faculty

Faculty

Rodney Hunter, PharmD, BCOP

  • Director of Clinical Services
  • Memorial Hermann Texas Medical Center
  • Clinical Pharmacy Specialist
  • University of Texas Health Memorial Hermann Cancer Center
  • Professor
  • Texas Southern University College of Pharmacy and Health Sciences
  • Clinical Adjunct Professor
  • McGovern Medical School
  • Houston, Texas
Faculty

Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, FASHP

  • Clinical Oncology Pharmacy Manager
  • Atrium Health Levine Cancer Institute
  • Charlotte, North Carolina
Faculty

Anthony J. Perissinotti, PharmD, BCOP

  • Hematology Clinical Pharmacist Specialist
  • University of Michigan
  • Ann Arbor, Michigan
Faculty

Julia L. Ziegengeist, PharmD, BCOP

  • Clinical Pharmacist Specialist, Breast Medical Oncology
  • Levine Cancer, Atrium Health
  • Charlotte, North Carolina

Accreditation

Translating Evidence Into Practice: Pharmacist-Led Optimization of Adjuvant CDK4/6 Therapy in High-Risk HR+/HER2- Early Breast Cancer

JOINT ACCREDITATION INTERPROFESSIONAL CONTINUING EDUCATION

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Pharmacy Education

Clinical Care Options, LLC dba Decera Clinical Education designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-26-164-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Targeting BCMA in Early Relapsed/Refractory Myeloma: What Oncology Pharmacists Need to Know Now and in the Near Future

Pharmacists

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-26-002-L01-P has been assigned to this live application-based activity (initial release date 4/30/2026). This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. This activity is provided at no cost to participants. Participants must complete the activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.deceraclinical.com/education, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure of Conflicts of Interest

Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgements

An independent, commercially supported symposium held in conjunction with the HOPA 2026 Annual Conference.

Translating Evidence Into Practice: Pharmacist-Led Optimization of Adjuvant CDK4/6 Therapy in High-Risk HR+/HER2- Early Breast Cancer
Provided by Clinical Care Options, LLC dba Decera Clinical Education
Supported by an educational grant from Lilly.

Targeting BCMA in Early Relapsed/Refractory Myeloma: What Oncology Pharmacists Need to Know Now and in the Near Future
Provided by ProCE, LLC
Supported by an educational grant from GSK.

Mailing Address
Decera Clinical
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191

For customer support please email:
customersupport@deceraclinical.com